Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1530477 | 0.84 | TTR (0.32) | TTRTPMT | |
| SCHEMBL351682 | 0.81 | PTGS2 (0.39) | CYP1A2TTRTPMT | |
| SCHEMBL708411 | 0.76 | TPMT (0.42) | HSD17B10TTRTPMT | |
| SCHEMBL13191049 | 0.76 | TTR (0.56) | CYP1A2CYP2C9HIF1AHSD17B10TTR | |
| SCHEMBL694843 | 0.75 | TPMT (0.38) | TTRTPMT | |
| SCHEMBL1530426 | 0.74 | — | — | |
| SCHEMBL1530694 | 0.73 | TTR (0.48) | TTRTPMTADRB2ADRB1ADRB3 | |
| SCHEMBL1530201 | 0.73 | TPMT (0.35) | TTRTPMT | |
| SCHEMBL12678948 | 0.70 | HSD17B10 (0.45) | HSD17B10TPMT | |
| SCHEMBL2065796 | 0.70 | PTGS2 (0.46) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8986740-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2368882-B1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBVIE BAHAMAS LTD (BS) | 2014-08-13 | — | — | EP | disclosed |
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741914-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2725015-A1 | Uracil or thymine derivative for treating hepatitis c | AbbVie Bahamas Ltd. (BS) | 2014-04-30 | — | — | EP | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2010111437-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203430-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CYP1A2 2937/4885CYP2C9 2170/4885HIF1A 3711/4885 |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CYP1A2 2937/4885CYP2C9 2170/4885HIF1A 3711/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | CYP1A2 2937/4885CYP2C9 2170/4885HIF1A 3711/4885 |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | MPO, ELANE, LPO | CYP1A2 2616/4885CYP2C9 1959/4885HIF1A 3727/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CYP1A2 2937/4885CYP2C9 2170/4885HIF1A 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.